Insider Transactions in Q2 2023 at Acelyrin, Inc. (SLRN)
Insider Transaction List (Q2 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 09
2023
|
Westlake Bio Partners Fund Ii, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
1,250,000
+11.32%
|
$22,500,000
$18.0 P/Share
|
|
May 09
2023
|
Westlake Bio Partners Fund Ii, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
8,540,729
+50.0%
|
-
|
|
May 09
2023
|
Dawn Svoronos Director |
BUY
Open market or private purchase
|
Direct |
15,000
+50.0%
|
$270,000
$18.0 P/Share
|
|
May 09
2023
|
Beth C Seidenberg Director |
BUY
Open market or private purchase
|
Direct |
60,000
+50.0%
|
$1,080,000
$18.0 P/Share
|
|
May 09
2023
|
Beth C Seidenberg Director |
BUY
Open market or private purchase
|
Indirect |
1,250,000
+11.32%
|
$22,500,000
$18.0 P/Share
|
|
May 09
2023
|
Beth C Seidenberg Director |
BUY
Conversion of derivative security
|
Indirect |
8,540,729
+50.0%
|
-
|
|
May 09
2023
|
Henry O Gosebruch Director |
BUY
Open market or private purchase
|
Direct |
50,000
+50.0%
|
$900,000
$18.0 P/Share
|
|
May 09
2023
|
Ronald Oyston Chief People Officer |
BUY
Open market or private purchase
|
Indirect |
26
+50.0%
|
$468
$18.0 P/Share
|
|
May 09
2023
|
Ronald Oyston Chief People Officer |
BUY
Open market or private purchase
|
Direct |
1,000
+50.0%
|
$18,000
$18.0 P/Share
|
|
May 09
2023
|
Daniel J. Becker Director |
BUY
Open market or private purchase
|
Direct |
3,000
+50.0%
|
$54,000
$18.0 P/Share
|
|
May 09
2023
|
Mina Kim Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+50.0%
|
$90,000
$18.0 P/Share
|
|
May 09
2023
|
Shao Lee Lin Chief Executive Officer |
BUY
Other acquisition or disposition
|
Indirect |
1,742,719
+50.0%
|
-
|
|
May 09
2023
|
Shao Lee Lin Chief Executive Officer |
SELL
Other acquisition or disposition
|
Indirect |
1,742,719
-100.0%
|
-
|
|
May 09
2023
|
Shao Lee Lin Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
337,179
-30.45%
|
$8,092,296
$24.69 P/Share
|
|
May 09
2023
|
Shao Lee Lin Chief Executive Officer |
BUY
Other acquisition or disposition
|
Direct |
1,107,213
+50.0%
|
-
|
|
May 09
2023
|
Shao Lee Lin Chief Executive Officer |
SELL
Other acquisition or disposition
|
Direct |
1,107,213
-100.0%
|
-
|
|
May 09
2023
|
Shao Lee Lin Chief Executive Officer |
BUY
Conversion of derivative security
|
Indirect |
1,161,747
+50.0%
|
-
|
|
May 09
2023
|
Mardi Dier CFO and CBO |
BUY
Open market or private purchase
|
Indirect |
1,750
+50.0%
|
$31,500
$18.0 P/Share
|
|
May 09
2023
|
Mardi Dier CFO and CBO |
BUY
Open market or private purchase
|
Direct |
5,556
+50.0%
|
$100,008
$18.0 P/Share
|
|
May 09
2023
|
Paul Peloso Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
6,000
+50.0%
|
$108,000
$18.0 P/Share
|
|
May 09
2023
|
Ayur Maya Capital Management Company, LP Director |
BUY
Conversion of derivative security
|
Indirect |
9,334,735
+50.0%
|
-
|